福斯米霉素（FR-31564）与其他抗菌剂的协同作用。
Synergy of fosmidomycin (FR-31564) and other antimicrobial agents.
作者信息
Neu H C, Kamimura T
出版信息
Antimicrob Agents Chemother. 1982 Oct;22(4):560-3. doi: 10.1128/AAC.22.4.560.
Abstract
Fosmidomycin (FR-31564), a phosphonic acid derivative, was combined with cefazolin, cephalexin, ampicillin, carbenicillin, ticarcillin, gentamicin, and trimethoprim. Synergy between fosmidomycin and penicillins or cephalosporins was found for 37 to 52% of the Enterobacteriaceae tested. Synergy with trimethoprim was found against 55% of bacteria isolated, but only 17% of the strains showed synergy between formidomycin and gentamicin. Synergy between fosmidomycin and ticarcillin was shown for 35% of the Pseudomonas isolates. Cefazolin-, ampicillin-, and gentamicin-resistant isolates of various species were synergistically inhibited by fosmidomycin, as were ticarcillin- and gentamicin-resistant isolates. Antagonism was not encountered. This study illustrates another example of synergistic activity of compounds which attack different mechanisms in bacterial cells.
摘要
磷霉素（FR - 31564），一种膦酸衍生物，与头孢唑林、头孢氨苄、氨苄西林、羧苄西林、替卡西林、庆大霉素和甲氧苄啶联合使用。在所测试的37%至52%的肠杆菌科细菌中发现磷霉素与青霉素或头孢菌素之间存在协同作用。发现与甲氧苄啶对55%的分离细菌有协同作用，但只有17%的菌株在磷霉素和庆大霉素之间表现出协同作用。在35%的铜绿假单胞菌分离株中显示出磷霉素与替卡西林之间的协同作用。各种物种对头孢唑林、氨苄西林和庆大霉素耐药的分离株以及对替卡西林和庆大霉素耐药的分离株均被磷霉素协同抑制。未发现拮抗作用。本研究说明了攻击细菌细胞中不同机制的化合物协同活性的另一个例子。
相似文献
1
Synergy of fosmidomycin (FR-31564) and other antimicrobial agents.福斯米霉素（FR-31564）与其他抗菌剂的协同作用。
Antimicrob Agents Chemother. 1982 Oct;22(4):560-3. doi: 10.1128/AAC.22.4.560.
2
In vitro and in vivo antibacterial activity of FR-31564, a phosphonic acid antimicrobial agent.膦酸类抗菌剂FR-31564的体外和体内抗菌活性
Antimicrob Agents Chemother. 1981 Jun;19(6):1013-23. doi: 10.1128/AAC.19.6.1013.
3
In vitro synergism of FR-31564, a new phosphonic acid antibiotic.新型膦酸类抗生素FR-31564的体外协同作用
J Antibiot (Tokyo). 1981 Jul;34(7):876-83. doi: 10.7164/antibiotics.34.876.
4
Synergy of fosfomycin with beta-lactam antibiotics against staphylococci and aerobic gram-negative bacilli.磷霉素与β-内酰胺类抗生素对葡萄球菌和需氧革兰氏阴性杆菌的协同作用。
Drugs Exp Clin Res. 1986;12(12):943-7.
5
Antibacterial activity of fosmidomycin on chromosomic and plasmid-determined fosfomycin-resistant strains.磷霉素对染色体和质粒介导的磷霉素耐药菌株的抗菌活性。
Chemioterapia. 1985 Apr;4(2):170-5.
6
Synergy of azlocillin and mezlocillin combined with aminoglycoside antibiotics and cephalosporins.阿洛西林和美洛西林与氨基糖苷类抗生素及头孢菌素的协同作用。
Antimicrob Agents Chemother. 1978 May;13(5):813-9. doi: 10.1128/AAC.13.5.813.
7
FR-31564, a new phosphonic acid antibiotic: bacterial resistance and membrane permeability.FR-31564，一种新型膦酸类抗生素：细菌耐药性与膜通透性
J Antibiot (Tokyo). 1980 Jan;33(1):44-8. doi: 10.7164/antibiotics.33.44.
8
Synergy of azlocillin with aminoglycosides.阿洛西林与氨基糖苷类药物的协同作用。
J Antimicrob Chemother. 1983 May;11 Suppl B:33-8. doi: 10.1093/jac/11.suppl_b.33.
9
Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions.氨基糖苷类药物与β-内酰胺类药物联合用于抗革兰氏阴性菌。体外协同作用及化学相互作用的评估。
Am J Med. 1986 Jun 30;80(6B):126-37. doi: 10.1016/0002-9343(86)90490-0.
10
In vitro and in vivo antibacterial activities of FR-31564, a new phosphonic acid antibiotic.新型膦酸抗生素FR-31564的体外和体内抗菌活性
J Antibiot (Tokyo). 1980 Jan;33(1):36-43. doi: 10.7164/antibiotics.33.36.
引用本文的文献
1
Development and application of an LC-MS/MS method for quantification of fosmidomycin in human and rat plasma.一种用于定量测定人血浆和大鼠血浆中磷霉素的液相色谱-串联质谱法的开发与应用。
Malar J. 2025 Jul 25;24(1):243. doi: 10.1186/s12936-025-05489-1.
2
Chemical biology-whole genome engineering datasets predict new antibacterial combinations.化学生物学-全基因组工程数据集预测新的抗菌组合。
Microb Genom. 2021 Dec;7(12). doi: 10.1099/mgen.0.000718.
3
Simultaneously inhibiting undecaprenyl phosphate production and peptidoglycan synthases promotes rapid lysis in Escherichia coli.同时抑制十一烯基磷酸的产生和肽聚糖合成酶可促进大肠杆菌的快速裂解。
Mol Microbiol. 2019 Jul;112(1):233-248. doi: 10.1111/mmi.14265. Epub 2019 May 6.
4
Targeting DXP synthase in human pathogens: enzyme inhibition and antimicrobial activity of butylacetylphosphonate.靶向人病原体中的 DXP 合酶：丁基乙酰膦酸盐的酶抑制和抗菌活性。
J Antibiot (Tokyo). 2014 Jan;67(1):77-83. doi: 10.1038/ja.2013.105. Epub 2013 Oct 30.
5
Further characterization of Bacillus subtilis antibiotic biosensors and their use for antibacterial mode-of-action studies.进一步研究枯草芽孢杆菌抗生素生物传感器及其在抗菌作用机制研究中的应用。
Antimicrob Agents Chemother. 2011 Apr;55(4):1784-6. doi: 10.1128/AAC.01710-10. Epub 2011 Jan 31.
6
Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malaria.对急性非复杂性恶性疟患者中磷霉素-克林霉素两种联合用药方案的药代动力学和药效学评估。
Malar J. 2008 Oct 31;7:225. doi: 10.1186/1475-2875-7-225.
7
Dxr is essential in Mycobacterium tuberculosis and fosmidomycin resistance is due to a lack of uptake.Dxr在结核分枝杆菌中至关重要，而对磷霉素的抗性是由于摄取不足所致。
BMC Microbiol. 2008 May 20;8:78. doi: 10.1186/1471-2180-8-78.
8
Pharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malaria.磷霉素单用及与克林霉素联合治疗耐多药恶性疟的药代动力学和药效学
Malar J. 2007 May 25;6:70. doi: 10.1186/1475-2875-6-70.
9
Antibacterial activity of cefmetazole alone and in combination with fosfomycin against methicillin- and cephem-resistant Staphylococcus aureus.头孢美唑单独及与磷霉素联合对耐甲氧西林和耐头孢菌素金黄色葡萄球菌的抗菌活性
Antimicrob Agents Chemother. 1986 Dec;30(6):917-22. doi: 10.1128/AAC.30.6.917.
本文引用的文献
1
FR-31564, a new phosphonic acid antibiotic: bacterial resistance and membrane permeability.FR-31564，一种新型膦酸类抗生素：细菌耐药性与膜通透性
J Antibiot (Tokyo). 1980 Jan;33(1):44-8. doi: 10.7164/antibiotics.33.44.
2
In vitro and in vivo antibacterial activities of FR-31564, a new phosphonic acid antibiotic.新型膦酸抗生素FR-31564的体外和体内抗菌活性
J Antibiot (Tokyo). 1980 Jan;33(1):36-43. doi: 10.7164/antibiotics.33.36.
3
In vitro synergism of FR-31564, a new phosphonic acid antibiotic.新型膦酸类抗生素FR-31564的体外协同作用
J Antibiot (Tokyo). 1981 Jul;34(7):876-83. doi: 10.7164/antibiotics.34.876.
4
In vitro and in vivo antibacterial activity of FR-31564, a phosphonic acid antimicrobial agent.膦酸类抗菌剂FR-31564的体外和体内抗菌活性
Antimicrob Agents Chemother. 1981 Jun;19(6):1013-23. doi: 10.1128/AAC.19.6.1013.
5
Synergy of mecillinam, a beta-amidinopenicillanic acid derivative, combined with beta-lactam antibiotics.β-脒基青霉素酸衍生物美西林与β-内酰胺类抗生素的协同作用。
Antimicrob Agents Chemother. 1976 Sep;10(3):535-42. doi: 10.1128/AAC.10.3.535.
6
Interactions of fosfomycin with other antibiotics.
Chemotherapy. 1977;23 Suppl 1:86-92. doi: 10.1159/000222031.
7
Interaction of fosfomycin with other antimicrobial agents: in vitro and in vivo studies.
J Antimicrob Chemother. 1978 Nov;4(6):569-76. doi: 10.1093/jac/4.6.569.
8
Synergism of fosfomycin-ampicillin and fosfomycin-chloramphenicol against Salmonella and Shigella.磷霉素-氨苄西林及磷霉素-氯霉素对沙门氏菌和志贺氏菌的协同作用。
Antimicrob Agents Chemother. 1978 May;13(5):705-9. doi: 10.1128/AAC.13.5.705.
Zotero 插件